Clinical Trial Details
EORTC-58111-CLG
Back to Clinical Trials Database
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010. A randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group
| Trial Status | Closed to Patient Entry |
|---|---|
| Dates |
Date of activation: 16-Mar-2016 Date Step1 close: 27-Mar-2020 |
| Data management at EORTC | No |
| Design |
Phase 3 Randomized open label |
| Targeted Sample size | EORTC Groups: 35 - All Groups: 612 |
| Treatment |
Drug Mercaptopurine, Tioguanine, Cyclophosphamide, Cytarabine, Daunorubicin, Etoposide, Idarubicin, Ifosfamide, Methotrexate, Mitoxantrone, Prednisolone, Vincristine, Dexamethasone, Epratuzumab, Crisantaspase |
| Study Staff |
Pierre Rohrlich (Study Coordinator) , CHU de Nice - Hopital De L'Archet, NICE Claire Gandilhon (Clinical Operations Assistant) , EORTC Headquarters, Brussels Eliza Starczewska (Junior RAM) , EORTC Headquarters, Brussels Laurens Vinckier (Pharmacovigilance Manager) , EORTC Headquarters, Brussels Gaetan de Schaetzen (Senior Clinical Operations Manager) , EORTC Headquarters, Brussels |
| Type of cancer | Acute Lymphocytic Leukemia |
| Participating groups |
EORTC Children's Leukemia Group Charite Universitaetsmedizin Berlin |
| Recruiting centers |
CHC MontLegia (Liege, Belgium) Centre Hospitalier Regional De La Citadelle (Liege, Belgium) Cliniques Universitaires Saint-Luc (Brussels, Belgium) U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium) Universitair Ziekenhuis Antwerpen (Edegem, Belgium) Universitair Ziekenhuis Brussel (Brussels, Belgium) Universitair Ziekenhuis Gent (Gent, Belgium) |
| Protocol summary | http://clinicaltrials.gov/study/ |
| NCT number | |
| EudraCT | 2012-000793-30 |
| Financial Support | EU Grant |
